ESBL infection, N (%)
|
27 (37.9)
|
24 (74.3)
|
4.1 [1.7–10.7] (< 0.01)
|
3.1 [0.8–12.5] (0.10)
|
Age, mean (SD)
|
54.2 (13.7)
|
53.8 (13.1)
|
1.0 [0.9–1.0] (0.89)
| |
Malea, N (%)
|
32 (46.4)
|
13 (39.4)
|
0.8 [0.3–1.7] (0.51)
|
0.5 [0.1–1.5] (0.20)
|
BMI at transplant (mean, SD)
|
25.0 (3.8)
|
25.9 (4.8)
|
1.0 [0.9–1.2] (0.33)
| |
Ethnicity: caucasian
|
66 (95.7)
|
29 (87.9)
|
0.3 [0.1–1.6] (0.16)
| |
Year of infection, N (%)
|
2012
|
8 (11.6)
|
6 (18.2)
|
–
| |
2013
|
17 (24.6)
|
7 (21.2)
|
0.6 [0.1–2.2] (0.39)
| |
2014
|
18 (26.1)
|
6 (18.2)
|
0.4 [0.1–1.8] (0.26)
| |
2015
|
17 (24.6)
|
9 (27.3)
|
0.7 [0.2–2.7] (0.61)
| |
2016
|
9 (13.0)
|
5 (15.2)
|
0.7 [0.2–3.4] (0.70)
| |
Transplanted organ, N (%)
|
Kidney
|
41 (59.4)
|
25 (75.8)
|
–
| |
Non-Kidney
|
28 (40.6)
|
8 (24.2)
|
0.4 [0.2–1.1] (0.09)
| |
Comorbidities, N (%)
|
Cardiopulmonary disease
|
9 (13.0)
|
5 (15.2)
|
1.2 [0.5–2.9] (0.62)
| |
Metabolic/endocrine disease
|
34 (49.3)
|
18 (54.5)
|
1.2 [0.5–3.5] (0.70)
| |
Cancer
|
52 (75.4)
|
26 (78.8)
|
1.2 [0.4–3.8] (0.77)
| |
Other
|
43 (62.3)
|
20 (60.6)
|
0.9 [0.4–2.2] (0.87)
| |
Causing pathogen, N (%)
|
Escherichia coli
|
54 (78.3)
|
23 (69.7)
|
–
| |
Klebsiella spp.
|
7 (10.1)
|
9 (27.3)
|
3.0 [1.0–9.4] (0.05)
| |
Other
|
8 (11.6)
|
1 (3.0)
|
0.3 [0.1–1.7] (0.26)
| |
Time to infection, median (IQR)
|
70 (31–256)
|
61 (14–203)
|
1.0 [1.0–1.0] (0.24)
| |
Type of infection, N (%)
|
Urinary tract (vs. other)
|
50 (72.5)
|
27 (81.8)
|
1.7 [0.6–5.2] (0.31)
| |
Bacteremia
|
19 (27.5)
|
8 (24.2)
|
0.8 [0.3–2.1] (0.72)
| |
Hospital-onset, N (%)
|
26 (38.2)
|
13 (39.4)
|
1.1 [0.4–2.5] (0.91)
| |
LOS after infectionb, median (IQR)
|
14 (4–26)
|
16 (7.2–33)
|
0.9 [0.9–1.0] (0.58)
| |
On ICU after infectiona, N (%)
|
10 (21.3)
|
7 (31.8)
|
1.7 [0.5–5.4] (0.35)
|
2.3 [0.6–8.1] (0.20)
|
Antibiotic therapyc, N (%)
|
60 (87.0)
|
28 (84.8)
|
0.8 [0.3–2.9] (0.77)
| |
Treatment with carbapenems
|
23 (33.3)
|
17 (51.5)
|
2.1 [0.9–5.0] (0.08)
| |
Treatment duration, median (IQR)
|
13 (7–19)
|
13 (7–18)
|
1.0 [0.9–1.0] (0.95)
| |
Adequate empiric therapya,d, N (%)
|
39 (65.0)
|
11 (39.3)
|
0.3 [0.1–0.9] (0.03)
|
0.5 [0.1–1.7] (0.27)
|
Infectious diseases consult, N (%)
|
36 (52.2)
|
13 (39.4)
|
0.6 [0.3–1.4] (0.23)
| |
Initially
|
27 (39.1)
|
10 (30.3)
|
0.7 [0.3–1.6] (0.39)
| |
Upon microbiology results
|
27 (39.1)
|
10 (30.3)
|
0.7 [0.3–1.6] (0.39)
| |